BioNTech Shares: Divergent Moves as Partner Exits and Analyst Backs Stock

While this large-scale sale might appear as a loss of confidence, Pfizer characterized the move as part of a broader strategic portfolio review. The U.S.-based company stated its intention to reallocate capital toward financing recent multi-billion dollar acquisitions, particularly in the oncology and obesity drug sectors.

In response, BioNTech maintained a composed public stance. A company spokesperson repeatedly emphasized the continuation of a “close and strong collaboration” with Pfizer, signaling Read more...